Additional indication for Dupixent
The blockbuster of Sanofin the Dupicent (dupilumab), received a fifth indication in Europe for the treatment of eosinophilic esophagitis. During its phase III, the patients presented a rate of histological remission approximately ten times higher, compared to that obtained with the placebo. The monoclonal antibody thus becomes the first and only targeted drug expressly indicated for the treatment of this pathology, which affects 50,000 people in the EU.
American green light for Lilly
The FDA has just authorized, according to an accelerated procedure, the Jaypirca (pirtobrutinib) d’Eli Lilly for the treatment of patients with relapsed or refractory mantle cell lymphoma, following at least two lines of systemic treatment. Patients pretreated with this Bruton’s tyrosine kinase (BTK) inhibitor in phase I/II clinical trials achieved an overall response rate of 50%, including 13% complete response.
VOS INDICES
source
Positive CHMP opinion for a Sandoz biosimilar
Novartis subsidiary Sandoz announced that it had received a favorable opinion from the CHMP of the EMA for the Marketing Authorization of its Hyrimoz (adalimumab), a biosimilar to Humira (adalimumab). The authorization covers all the indications covered by the reference drug: rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis and uveitis. In 2021, sales of the Humira amounted to $20.7bn.
Selected for you
